Please login to the form below

Not currently logged in

Vertex appoints new commercial lead amid NHS, Orkambi price war

Ludovic Fenaux will succeed Simon Bedson


Vertex’s commercial lead Simon Bedson (pictured above) is set to retire from his post as senior vice president and general manager, international commercial operations, after seven years’ service with the company.

Bedson has spent almost a quarter of his time with Vertex locked in negotiations with England’s National Health Service (NHS) after its cost effectiveness watchdog NICE rejected Vertex’s pricing proposition of cystic fibrosis drug Orkambi back in 2016.

The dispute has culminated to NHS England calling the company out, asking it to waive its non-disclosure to reveal Orkambi’s cost.

For now, it seems as if the row has hit a stalemate.

Lined up to take the reins from Bedson, however, is former Bristol-Myers Squibb senior VP, head of intercontinental region, Ludovic Fenaux (pictured below).


Although there is no word on how Fenaux is expected to handle the ongoing Orkambi row, chief commercial officer Stuart Arbuckle seems confident in his abilities.

He said: “I am thrilled to welcome Ludovic to Vertex and our global commercial leadership team. Ludovic brings the leadership skills and functional and geographic experience our growing international organisation needs as we become a leading global biotechnology company.”

Fenaux has spent more than two decades within the pharmaceutical industry, previously holding positions for companies including Eli Lilly, AstraZeneca and GlaxoSmithKline.

Commenting on his new appointment, Fenaux said: “I am excited to be joining Vertex at a time when the company is not only pursuing medicines that treat cystic fibrosis but also investing in other serious diseases, tackling the biggest challenges in medicine.

“I look forward to being part of an industry leader, driven by an understanding of human biology, to progress scientific innovations that address the underlying cause of disease.”

Article by
Gemma Jones

23rd August 2018

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....